摘要
目的分析不同二线治疗方案对小细胞肺癌(SCLC)患者临床疗效研究。方法选取SCLC患者226例,将患者分为两组,观察组(113例)采用含TPT治疗方案,对照组(113例)采用为CPT-11治疗方案,观察术后治疗效果,总生存时间(OS),无进展生存时间(PFS),疾病控制率(DCR)及客观缓解率(ORR)。结果两组患者在分期、年龄、吸烟史、体力评分及性别等方面对比差异无统计学意义(P> 0.05);观察组患者ORR、DCR、PFS及OS均高于对照组,差异有统计学意义(P <0.05);对照组患者发生Ⅲ、Ⅳ度腹泻人数多于观察组,对比差异有统计学意义(P <0.05)。结论一线治疗失败的SCLC患者进行以托泊替康为主的二线治疗其生存期可获益,无进展生存时间和近期缓解率高于其他化疗方案。
Objective To analyze the clinical efficacy of different second-line treatment regimens in patients with small cell lung cancer (SCLC). Methods Select the 226 cases of SCLC patients,patients were divided into 2 groups,(113 cases) TPT-containing regimen,the control group (113 cases) to CPT-11 treatment regimen,postoperative treatment,overall survival (OS ),progression-free survival (PFS),disease control rate (DCR) and objective response rate (ORR). Results There were no significant differences in the staging,age,smoking history,physical score and gender between the two groups ( P >0.05).The ORR,DCR,PFS and OS of the observation group were higher than the control group,the difference was statistically significant.( P <0.05);the number of patients with III and IV diarrhea in the control group was higher than that in the observation group,and the difference was statistically significant ( P <0.05). Conclusion Patients with SCLC who failed first-line treatment were benefited from second-line treatment with topotecan,and progression-free survival and recent remission were higher than other chemotherapy regimens.
作者
韩鹏
武淮昌
许志强
HAN Peng;WU Huaichang;XU Zhiqiang(Anyang District Hospital,Anyang,455000)
出处
《实用癌症杂志》
2019年第1期86-88,共3页
The Practical Journal of Cancer
关键词
小细胞肺癌
二线化疗
近期疗效
远期生存差异
Small cell lung cancer
Second-line chemotherapy
Short-term efficacy
Long-term survival differences
